Welcome to our dedicated page for Twist Bioscience SEC filings (Ticker: TWST), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Twist Bioscience Corporation filings document formal disclosures for a synthetic biology company with a silicon-based DNA synthesis platform. Form 8-K reports furnish quarterly and annual financial results, preliminary revenue information and business highlights tied to products and services such as synthetic DNA, NGS workflow tools and antibody discovery solutions.
The filing record also covers unregistered common stock issuances connected to licensing and technology-transfer arrangements, annual meeting voting results, director elections, auditor ratification, executive compensation votes, board appointments, committee service and director compensation. These disclosures address governance, capital structure and material events for TWST common stock.
Form 144 notice shows an insider proposes to sell 31,348 shares of common stock, with an aggregate market value of $1,008,998.08, representing approximately 0.052% of the 60,360,925 shares outstanding. The shares were acquired through restricted stock vesting on 10/01/2025 and the approximate sale date is 10/06/2025. The filing lists prior insider sales in the past three months totaling 12,746 shares for gross proceeds of $348,121.10, with individual sale dates between 08/04/2025 and 10/02/2025. The filer attests there is no undisclosed material adverse information and notes the securities were received as compensation.
Twist Bioscience Corp (TWST) submitted a Form 144 notice reporting a proposed sale of 2,041 common shares with an aggregate market value of $65,693.67, planned for 10/06/2025 on NASDAQ. The shares were acquired on 10/01/2025 through restricted stock vesting and the stated nature of payment is compensation. The filer also disclosed four earlier open-market sales by the same person between 08/04/2025 and 09/08/2025, totaling 1,511 shares and gross proceeds of $41,029.46. The notice includes the usual representation that the seller is not aware of undisclosed material adverse information.
Twist Bioscience Corp (TWST) filed a Form 144 reporting a proposed sale of 23,747 common shares with an aggregate market value of $764,344.69, representing part of shares acquired by restricted stock vesting on 10/01/2025. The filing lists the intended approximate sale date as 10/06/2025 on NASDAQ. It also discloses recent insider sales by Patrick Finn totaling 7,467 shares across 07/23/2025, 08/04/2025, 08/21/2025, and 10/02/2025 with combined gross proceeds visible in the table. The filer contact and CIK fields appear incomplete in the form, and no earnings or corporate operational details are included.
Twist Bioscience (TWST) filed a Form 144 reporting a proposed sale of 9,724 common shares with an aggregate market value of $312,986.38, to be sold through Fidelity Brokerage Services LLC on 10/06/2025 on NASDAQ. The shares were acquired on 10/01/2025 through restricted stock vesting and were paid as compensation.
The filing also discloses prior sales by the same person, Paula Green, totaling 3,201 shares sold across five trades between 08/04/2025 and 10/02/2025, generating $86,859.32 in gross proceeds. The company-wide share count reported in the notice is 60,360,925 shares outstanding. The filer certifies no undisclosed material adverse information.
Notice of proposed insider sale: A Form 144 was filed for common stock of Twist Bioscience Corp (TWST) showing a proposed sale of 3,876 shares with an aggregate market value of 124,756.81, listing NASDAQ as the exchange and an approximate sale date of 10/06/2025. The shares were acquired on 10/01/2025 by restricted stock vesting as compensation from the issuer.
The filing lists prior open-market disposals by the same account (Dennis H. Cho) in the past three months totaling 2,026 shares sold across six trades between 08/04/2025 and 10/02/2025, producing gross proceeds shown per trade. The filer certifies no undisclosed material adverse information and includes the standard attestation language required by Rule 144.
Dennis Cho, Senior Vice President and Chief Legal Officer of Twist Bioscience Corporation (TWST), reported a sale of 124 shares of Common Stock on 10/02/2025. The transaction is described as a sell-to-cover executed to satisfy tax withholding on vested restricted stock units rather than a discretionary sale. The reported sale price was $29.161 per share and the reporting person retained 102,586 shares after the transaction. The form is signed by an attorney-in-fact and discloses the reporter's officer role.
Paula Green, who serves as SVP of Human Resources and a director at Twist Bioscience Corp (TWST), reported a mandated sell-to-cover transaction tied to the vesting of restricted stock units. On 10/02/2025 she disposed of 140 shares of common stock at $29.161 per share to satisfy tax withholding, leaving her with 124,402 shares beneficially owned after the sale. The Form 4 was signed by an attorney-in-fact on 10/06/2025.
The filing explicitly states the sale was not a discretionary trade but a company-mandated sale under the issuer's equity plan to cover tax obligations arising from RSU vesting. No options, warrants, or other derivative transactions are reported on this form.
Emily M. Leproust, Chief Executive Officer and Director of Twist Bioscience Corporation (TWST), reported a small non-discretionary sale of shares to cover tax withholding related to vested restricted stock units. The filing shows a sale of $29.161 per share for 476 shares on 10/02/2025, described as a mandatory "sell to cover" to satisfy tax withholding; these sales were not discretionary trades by the reporting person. After the transaction, the reporting person beneficially owned 632,560 shares of common stock.
The Form 4 also lists outstanding employee stock options and performance options with various exercise prices and vesting/exercise dates, including options exercisable immediately and a granted performance option that vested on 12/19/2022. The report was signed by an attorney-in-fact on 10/06/2025.
Patrick John Finn, President and COO of Twist Bioscience Corp (TWST), reported a sale of $29.161-priced common stock on 10/02/2025. The Form 4 shows 206 shares were sold to satisfy tax withholding obligations tied to vested Restricted Stock Units; the filing states these were mandatory 'sell to cover' transactions rather than discretionary trades. Following the transaction and an administrative correction, the reporting person beneficially owns 232,482 shares. The Form 4 was filed by counsel on 10/06/2025 and is signed by an attorney-in-fact.
Twist Bioscience insider filings show a proposed sale under Rule 144 and multiple recent disposals of common stock. The notice reports an intended sale of 140 shares through Fidelity Brokerage Services with an approximate sale date of 10/02/2025 and an aggregate market value of $4,082.53. The shares were acquired on 10/01/2025 by restricted stock vesting and were paid as compensation. The filer also disclosed five prior sales by Paula Green between 07/02/2025 and 09/22/2025, totaling 3,203 shares and gross proceeds of $86,716.21. The filing records 60,360,925 shares outstanding for the issuer and includes the required attestation that no undisclosed material adverse information is known to the seller.